{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:15:06Z","timestamp":1771658106797,"version":"3.50.1"},"reference-count":44,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p> Selection of first-line antiretroviral therapy requires consideration of efficacy as well as effects on lipids given the increased concern about cardiovascular risk in HIV-1 patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir\/ritonavir (ATZ\/r) 300 mg\/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg\/ emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4<jats:sup>+<\/jats:sup> T-cell counts &lt;400 (men) and &lt;250 cells\/mm<jats:sup>3<\/jats:sup> (women). The primary end point was plasma HIV RNA&lt;50 copies\/ml at two consecutive visits prior to week 48. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A total of 569 patients were randomized and treated. Overall, 66.8% of NVP and 65.3% of ATZ\/r patients achieved the primary end point (difference 1.9%, 95% CI -5.9\u20139.8%). Similar rates of serious adverse events were observed (9.6% on NVP versus 8.8% on ATZ\/r), although discontinuations due to adverse events were more frequent with NVP than ATZ\/r (13.6% versus 3.6%, respectively). None of the 28 patients virologically failing ATZ\/r selected resistance mutations, while they were selected in 29\/44 patients virologically failing NVP. NVP induced a significantly greater increase in high-density lipoprotein cholesterol (HDL-c) and apolipoprotein A1 from baseline than ATZ\/r, whereas triglycerides increased significantly more with ATZ\/r than NVP. Mean change from baseline in TC:HDL-c ratio was -0.24 for NVP and 0.13 for ATZ\/r ( P=0.0001). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p> NVP demonstrated at week 48 non-inferior antiviral efficacy compared with ATZ\/r when given along with TDF\/FTC, despite more drug-related discontinuations with NVP than ATZ\/r. NVP was associated with a lower atherogenic lipid profile than ATZ\/r although resistance mutations were more frequently selected with NVP than ATZ\/r. <\/jats:p><\/jats:sec>","DOI":"10.3851\/imp1745","type":"journal-article","created":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T17:32:06Z","timestamp":1299259926000},"page":"339-348","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":83,"title":["Nevirapine versus Atazanavir\/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate\/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial"],"prefix":"10.1177","volume":"16","author":[{"name":"ARTEN investigators","sequence":"first","affiliation":[]},{"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain"}]},{"given":"Keikawus","family":"Arast\u00e9h","sequence":"additional","affiliation":[{"name":"Epimed GmbH, Berlin, Germany"}]},{"given":"Horacio","family":"Migrone","sequence":"additional","affiliation":[{"name":"Infectolog\u00eda de Asistencia Ambulatoria, Buenos Aires, Argentina"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[{"name":"Infektiologicum Frankfurt, Frankfurt, Germany"}]},{"given":"Milos","family":"Opravil","sequence":"additional","affiliation":[{"name":"Department Internal Medicine, University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland"}]},{"given":"Jaime","family":"Andrade-Villanueva","sequence":"additional","affiliation":[{"name":"Antiguo Hospital Civil, Guadalajara, Mexico"}]},{"given":"Francisco","family":"Antunes","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Doen\u00e7as Infecciosas, Hospital de Santa Maria, Lisbon, Portugal"}]},{"given":"Giovanni Di","family":"Perri","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Torino, Torino, Italy"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Universitario de Bellvitge, Barcelona, Spain"}]},{"given":"Steve","family":"Taylor","sequence":"additional","affiliation":[{"name":"Directorate of Infection, Birmingham Heartlands Hospital, Birmingham, UK"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[{"name":"HIV Unit, Hospital de Sant Pau, Barcelona, Spain"}]},{"given":"Holger","family":"Gellermann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim GmbH, Ingelheim, Germany"}]},{"given":"Lothar","family":"de Rossi","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim GmbH, Ingelheim, Germany"}]}],"member":"179","published-online":{"date-parts":[[2010,4,1]]},"reference":[{"key":"bibr1-IMP1745","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1004"},{"key":"bibr2-IMP1745","unstructured":"European AIDS Clinical Society. HIV guidelines (Updated November 2009. Accessed 1 December 2010.) Available from http:\/\/www.europeanaidsclinicalsociety.org\/guidelines.asp."},{"key":"bibr3-IMP1745","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00636.x"},{"key":"bibr4-IMP1745","unstructured":"US Department of Health and Human Services. Panel on Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 1 December 2009. Accessed 1 December 2010.) Available from http:\/\/www.aidsinfo.nih.gov\/."},{"key":"bibr5-IMP1745","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn252"},{"key":"bibr6-IMP1745","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15997-7"},{"key":"bibr7-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280121ab1"},{"key":"bibr8-IMP1745","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/135965350200700202","volume":"7","author":"Podzamczer D.","year":"2002","journal-title":"Antivir Ther"},{"key":"bibr9-IMP1745","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021589"},{"key":"bibr10-IMP1745","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.192088"},{"key":"bibr11-IMP1745","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61081-8"},{"key":"bibr12-IMP1745","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902980202"},{"key":"bibr13-IMP1745","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm413"},{"key":"bibr14-IMP1745","doi-asserted-by":"publisher","DOI":"10.1086\/517497"},{"key":"bibr15-IMP1745","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2010.00827.x"},{"key":"bibr16-IMP1745","unstructured":"Division of A.I.D.S. Table for grading the severity of adult and pediatric adverse events. (Updated December 2009. Accessed 10 May 2010.) Available from www.niaid.nih.gov\/research\/resources\/DAIDSClinRsrch\/PDF\/Safety\/DAIDSAEGradingTable.pdf."},{"key":"bibr17-IMP1745","unstructured":"European AIDS Clinical Society. European guidelines for the clinical management and treatment of HIV infected adults. 2005. (Accessed 10 May 2010.) Available from www.europeanaidsclinicalsociety.org\/guidelines.asp."},{"key":"bibr18-IMP1745","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/135965350701200612","volume":"12","author":"Battegay M.","year":"2007","journal-title":"Antivir Ther"},{"key":"bibr19-IMP1745","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn169"},{"key":"bibr20-IMP1745","unstructured":"US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for industry. Antiretroviral drugs using plasma HIV RNA measurements \u2013 clinical considerations for accelerated and traditional approval. (Updated October 2002. Accessed 10 December 2009.) Available from http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070968.pdf."},{"key":"bibr21-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830285fb"},{"key":"bibr22-IMP1745","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn471"},{"key":"bibr23-IMP1745","doi-asserted-by":"publisher","DOI":"10.1086\/529394"},{"key":"bibr24-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283322895"},{"key":"bibr25-IMP1745","unstructured":"McIntyre J., Hughes M., Mellors J. Efficacy of ART with NVP+TDF\/FTC vs LPV\/r+TDF\/FTC among antiretroviral-naive women in Africa: OCTANE Trial 2\/ACTG A5208. 17th Conference on Retroviruses and Opportunistic Infections. 16\u201319 February 2010, San Francisco, CA, USA. Abstract 153LB."},{"key":"bibr26-IMP1745","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a3172"},{"key":"bibr27-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328320a849"},{"key":"bibr28-IMP1745","doi-asserted-by":"publisher","DOI":"10.1086\/649897"},{"key":"bibr29-IMP1745","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062744"},{"key":"bibr30-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328339192f"},{"key":"bibr31-IMP1745","doi-asserted-by":"publisher","DOI":"10.1086\/378131"},{"key":"bibr32-IMP1745","first-page":"15","volume":"14","author":"Moyle G.J.","year":"2004","journal-title":"AIDS Read"},{"key":"bibr33-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328133f081"},{"key":"bibr34-IMP1745","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.02.041"},{"key":"bibr35-IMP1745","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi077"},{"key":"bibr36-IMP1745","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-5-5"},{"key":"bibr37-IMP1745","doi-asserted-by":"publisher","DOI":"10.1310\/hct0905-324"},{"key":"bibr38-IMP1745","first-page":"46","volume":"17","author":"Letendre S.L.","year":"2009","journal-title":"Top HIV Med"},{"key":"bibr39-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328317a702"},{"key":"bibr40-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32814e6b1c"},{"key":"bibr41-IMP1745","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009080-00014"},{"key":"bibr42-IMP1745","doi-asserted-by":"publisher","DOI":"10.1310\/hct0706-309"},{"key":"bibr43-IMP1745","unstructured":"WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. (Updated 30 November 2009. Accessed 10 May 2010.) Available from http:\/\/www.who.int\/hiv\/pub\/arv\/advice\/en\/index.html."},{"key":"bibr44-IMP1745","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1418"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1745","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T06:34:40Z","timestamp":1741674880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP1745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.3851\/IMP1745"],"URL":"https:\/\/doi.org\/10.3851\/imp1745","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,1]]}}}